NK cell therapy targeting NY-ESO-1 for sarcomas
Treatments studied
Part of Cancer clinical trials.
This trial tests a new kind of immune therapy using your own natural killer (NK) cells that are specially trained to find and attack cancer cells that have the NY-ESO-1 target. It is for people with certain sarcomas or other advanced solid tumors that have not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a specific marker (HLA-A*02:01, 02:05, or 02:06) and produce a protein called NY-ESO-1 in at least half of the cancer cells.
- You must have already received at least one round of standard treatment (like chemotherapy) for your cancer.
- You need to be between 16 and 80 years old and weigh at least 40 kg (about 88 lbs).
- You should be in fairly good health overall, with adequate heart, liver, kidney, and blood cell function.
- You must not have serious active infections, uncontrolled autoimmune disease, or other major health problems that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
This trial tests a new treatment using cord blood immune cells (NK cells) that are specially designed to target a protein called NY-ESO-1 found on myeloma cells. It is for people with multiple myeloma that has come back or not responded to at least two previous treatments.
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
Hear when a new Synovial Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.